AR087451A1 - Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes - Google Patents

Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes

Info

Publication number
AR087451A1
AR087451A1 ARP120102845A ARP120102845A AR087451A1 AR 087451 A1 AR087451 A1 AR 087451A1 AR P120102845 A ARP120102845 A AR P120102845A AR P120102845 A ARP120102845 A AR P120102845A AR 087451 A1 AR087451 A1 AR 087451A1
Authority
AR
Argentina
Prior art keywords
tetrahydroquinoline
diabetes
derived
useful
treatment
Prior art date
Application number
ARP120102845A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR087451(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR087451A1 publication Critical patent/AR087451A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP120102845A 2011-08-17 2012-08-03 Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes AR087451A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161524462P 2011-08-17 2011-08-17

Publications (1)

Publication Number Publication Date
AR087451A1 true AR087451A1 (es) 2014-03-26

Family

ID=46690732

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102845A AR087451A1 (es) 2011-08-17 2012-08-03 Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes

Country Status (30)

Country Link
US (1) US8431706B2 (enExample)
EP (1) EP2744806B1 (enExample)
JP (1) JP5903162B2 (enExample)
KR (1) KR101570624B1 (enExample)
CN (1) CN103687856B (enExample)
AP (1) AP3589A (enExample)
AR (1) AR087451A1 (enExample)
AU (1) AU2012295372A1 (enExample)
BR (1) BR112014003079A2 (enExample)
CA (1) CA2843474C (enExample)
CL (1) CL2014000357A1 (enExample)
CO (1) CO6880069A2 (enExample)
CR (1) CR20140052A (enExample)
DO (1) DOP2014000018A (enExample)
EA (1) EA022165B1 (enExample)
EC (1) ECSP14013211A (enExample)
ES (1) ES2578165T3 (enExample)
GT (1) GT201400022A (enExample)
IL (1) IL230635A (enExample)
IN (1) IN2014MN00191A (enExample)
MA (1) MA35351B1 (enExample)
MX (1) MX2014001832A (enExample)
PE (1) PE20140831A1 (enExample)
PH (1) PH12014500366A1 (enExample)
SG (1) SG11201401793PA (enExample)
TN (1) TN2014000058A1 (enExample)
TW (1) TWI537262B (enExample)
UA (1) UA110983C2 (enExample)
WO (1) WO2013025424A1 (enExample)
ZA (1) ZA201400705B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3068788A1 (en) 2013-11-14 2016-09-21 Cadila Healthcare Limited Novel heterocyclic compounds
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
WO2019134984A1 (en) 2018-01-08 2019-07-11 Celon Pharma S.A. 3-phenyl-4-hexynoic acid derivatives as gpr40 agonists
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020242252A1 (ko) 2019-05-31 2020-12-03 현대약품 주식회사 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 결정형
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
WO2021083270A1 (zh) * 2019-10-31 2021-05-06 中国石油化工股份有限公司 负载型催化剂及其制备方法和应用
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS
KR102699076B1 (ko) * 2021-04-01 2024-08-27 현대약품 주식회사 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도
CN115317484B (zh) * 2022-08-26 2023-07-18 北京箭牧科技有限公司 Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用
CN115671105B (zh) * 2022-11-22 2023-10-27 北京箭牧科技有限公司 Ly2922470在制备预防或治疗肾脏疾病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
EP1379523B1 (en) * 2001-03-27 2005-07-27 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
EA011010B1 (ru) * 2004-02-27 2008-12-30 Эмджен, Инк. Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
WO2005087710A1 (ja) * 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
EP2253315A1 (en) * 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
KR101570624B1 (ko) 2015-11-19
CL2014000357A1 (es) 2014-09-05
AP3589A (en) 2016-02-15
US8431706B2 (en) 2013-04-30
JP5903162B2 (ja) 2016-04-13
IL230635A (en) 2015-11-30
WO2013025424A1 (en) 2013-02-21
SG11201401793PA (en) 2014-09-26
EP2744806B1 (en) 2016-04-27
EA022165B1 (ru) 2015-11-30
KR20140041835A (ko) 2014-04-04
TW201319060A (zh) 2013-05-16
UA110983C2 (uk) 2016-03-10
TN2014000058A1 (en) 2015-07-01
ES2578165T3 (es) 2016-07-21
EA201490269A1 (ru) 2014-05-30
CN103687856B (zh) 2015-07-22
PE20140831A1 (es) 2014-07-14
ZA201400705B (en) 2015-11-25
GT201400022A (es) 2015-01-16
MX2014001832A (es) 2014-02-27
CO6880069A2 (es) 2014-02-28
AP2014007436A0 (en) 2014-02-28
BR112014003079A2 (pt) 2017-02-21
US20130045990A1 (en) 2013-02-21
NZ621248A (en) 2015-08-28
CR20140052A (es) 2014-06-20
IN2014MN00191A (enExample) 2015-08-21
CA2843474C (en) 2015-12-15
EP2744806A1 (en) 2014-06-25
PH12014500366A1 (en) 2014-04-14
IL230635A0 (en) 2014-03-31
CA2843474A1 (en) 2013-02-21
MA35351B1 (fr) 2014-08-01
JP2014521744A (ja) 2014-08-28
DOP2014000018A (es) 2014-04-15
ECSP14013211A (es) 2014-03-31
AU2012295372A1 (en) 2014-01-23
TWI537262B (zh) 2016-06-11
CN103687856A (zh) 2014-03-26

Similar Documents

Publication Publication Date Title
CR20140052A (es) Un derivado novedoso de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
MY170713A (en) Treatment protocol of diabetes type 2
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
PH12017500533A1 (en) 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators
NI201200195A (es) Procedimiento de preparación de la sal de l - arginina de perindoprilo
CR20140325A (es) Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2-
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
PH12016502568A1 (en) Novel heterocyclic compound
MX2015005739A (es) Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2.
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).
EA201690908A1 (ru) Пиразолопиримидиновые соединения
AR098134A1 (es) Compuestos de urea
WO2014147578A3 (en) Antibacterial compounds against drug resistant bacteria
MX2014004853A (es) 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos.
TN2014000307A1 (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors

Legal Events

Date Code Title Description
FB Suspension of granting procedure